Haematology 2018

RELEVANCE: RESPONSE BY IRC (ITT) (CO-PRIMARY ENDPOINT)

Co-Primary Endpoint: CR/CRu at 120 weeks

Best CR/CRu

Best ORR

P = 0.13

89%

100%

100%

100%

84%

80%

80%

80%

67%

59%

53%

60%

60% 48%

60%

40%

40%

40%

Response, %

Response, %

Response, %

20%

20%

20%

0%

0%

0%

R-chemo (n = 517)

R-chemo (n = 517)

R-chemo (n = 517)

R 2 (n = 513)

R 2 (n = 513)

R 2 (n = 513)

• 3-year DOR was 77% for R 2 vs 74% R-chemo (IRC) • Investigator results were consistent with IRC

Data cut-off31May2017. Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R 2 ) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWith Previously Untreated FollicularLymphoma. Oral presentation at:American Society of ClinicalOncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.